bluebird bio (NASDAQ:BLUE) encountered a rise of 6.7% or 474,223 shares in the short positions. The number escalated from 7,109,868 on May 31,2016 to 7,584,091 on June 15,2016. The final interest is 20.9% of the floated stock. The days to cover figure of 11 can be arrived using the average daily exchange of 722,188 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
bluebird bio (NASDAQ:BLUE): The stock opened at $39.66 on Friday but the bulls could not build on the opening and the stock topped out at $41.69 for the day. The stock traded down to $39.66 during the day, due to lack of any buying support eventually closed down at $40.77 with a loss of -3.50% for the day. The stock had closed at $42.25 on the previous day. The total traded volume was 4,089,325 shares.
The company shares have dropped -74.40% from its 1 Year high price. On Jul 15, 2015, the shares registered one year high at $171.24 and the one year low was seen on May 12, 2016. The 50-Day Moving Average price is $41.87 and the 200 Day Moving Average price is recorded at $47.71.
Stocks of bluebird bio (NASDAQ:BLUE) rallied by 2.51% during the past week but lost 7.66% on a 4-week basis. The company has outperformed the S&P 500 by 4.22% in the past week but underperformed the index by 4.86% in the last 4 weeks.
bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing products based on the transformative potential of gene therapy to treat patients with severe genetic diseases and cancer. The Companys products include Lenti-D, LentiGlobin and CAR T Cells. The Company is developing Lenti-D to treat patients with CCALD (Childhood cerebral adrenoleukodystrophy), the severe form of ALD (Adrenoleukodystrophy). The Company is conducting a Phase II/III clinical study of Lenti-D in the United States. The Company is developing LentiGlobin to treat patients with b-thalassemia and severe SCD (sickle cell disease). The Company is conducting a Phase I/II clinical study of LentiGlobin. It also initiated a second Phase I/II clinical study in the United States, Australia and Thailand for LentiGlobin. The Company is developing CAR T cell technology to deliver T cells engineered to kill the cancer.